Martin Shkreli fails to overturn lifetime pharma ban — again; Daiichi Sankyo and ViGeneron re-up eye disease deal
Martin Shkreli has once again been unable to convince a judge to overturn his lifetime pharma industry ban.
Shkreli had attempted to put the ban on hold while he appealed a 2020 conviction regarding his activities related to Daraprim, but judge Denise Cote of the Southern District of New York was not swayed. Cote is the same judge who handed down the original ban in January and upheld it a few weeks later.
“Shkreli contends once more that the Injunction is overbroad, punitive, and vague,” Cote wrote in the case. “Those objections were addressed in the February 4 Opinion and Shkreli raises no new arguments.”
One thing that was different, however, is that Shkreli is now representing himself in the case after his attorneys backed out earlier this month, according to a report from Bloomberg Law.
Monday’s rejection comes after Shkreli received a lifetime industry ban, as well as a ban from running any public company. In upholding the pharma ban in February, Cote had determined that any public statement Shkreli makes could be deemed an attempt to influence the market.
Shkreli had been sued by the FTC and seven states in 2020, accused of essentially running a drug monopoly from prison. Shkreli, regulators and states said, attempted to prevent Daraprim generics from reaching the market by blocking competitors’ access to a key ingredient.
Cote ultimately found Shkreli and his company, Vyera Pharmaceuticals, had illegally made $64.6 million in illegal profits with the scheme.
Daiichi Sankyo and ViGeneron re-up eye disease collaboration
Daiichi Sankyo is returning to a biotech partner with an expanded agreement.
The company is teaming up once again with ViGeneron to develop a gene therapy for prevalent eye diseases, the biotech said in a Tuesday press release. The two have worked together on the therapy since early 2021 and are now expanding the deal to evaluate ViGeneron’s AAV tech in animal studies. Financial terms of the deal were not disclosed.
“Based on our partnership and findings, to date, we look forward to a successful follow-on collaboration with Daiichi Sankyo and potentially to developing a new sustained therapy that will address a dire need for many patients suffering from prevalent eye diseases,” ViGeneron CEO Caroline Man Xu said in a statement.
Tuesday’s deal is ViGeneron’s second notable eye disease collaboration this month after it partnered with Regeneron. ViGeneron did not disclose details about financing or expected targets in that deal.